Market Signal Briefing

Nyxoah Announces First U.S. Commercial Patients Implanted with Genio® System

Early Commercial Launch Demonstrates Strong Physician Demand, Successful Pre-Authorizations, and Widespread Payor Coverage

Mont-Saint-Guibert, Belgium – October 6, 2025 7:00 CET / 1:00 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that the first U.S. commercial patients have been successfully implanted with the Genio® system following FDA approval.

"We are thrilled to announce that the first commercial patients have now received Genio implants, marking a significant milestone in bringing this innovative therapy to OSA patients in the U.S.," said Olivier Taelman, Chief Executive Officer. "Importantly, we have trained surgeons, obtained Value Analysis Committee (VAC) approvals and achieved successful coverage from major payors including CMS. What's also particularly encouraging is the strong demand we're seeing from physicians, with surgeons actively reaching out for training opportunities, many of whom already have patients lined up for implants. These early leading indicators give us confidence that we're building the right foundation for the sustained adoption of Genio moving forward.”

Andrew T. Huang, MD FACS, Director of Sleep Surgery at Baylor College of Medicine implanted the first Genio devices at Townsen Memorial Health System in Houston, TX. “I am excited to not only be the first surgeon to perform Genio® implants commercially in the United States but to have completed my first five in one week. It was awesome to see the powerful and symmetric tongue protrusion at the end of each procedure. Like with any new procedure, there is a learning curve, but I’m excited to say the cases took me the same amount of time as my first unilateral HGN implants. The Genio system provides a solution for my patients who do not want two incisions, an implanted battery, and those where bilateral stimulation may be more beneficial to their airway anatomy.,” commented Dr. Huang. “Obstructive sleep apnea continues to represent a significant health burden in our country, and expanding access to new therapeutic options is essential. I am happy this therapy is now available in the US and am honored to help improve access to Genio Therapy by offering it to my patients and helping to train more providers on this amazing procedure.”

The Company is tracking the following metrics which it believes will serve as leading indicators of future revenue growth:

Number of surgeons trained; Number of value analysis committee submissions made; Number of prior authorization submissions; andNumber of accounts opened. About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and U.S. FDA approval of a Premarket Approval application.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.

FORWARD-LOOKING STATEMENTS

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the Genio system; planned and ongoing clinical studies of the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; the Company’s intellectual property portfolio; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2025, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, or adverse litigation outcomes can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:

Nyxoah
John Landry, CFO
[email protected]

ENGLISH_NYXH_Genio First US Patient PR_FINAL

Curtiss-Wright Corporation continues to benefit from strong aerospace, defense, and nuclear energy market tailwinds, driving robust sales and margin growth. CW raised its full-year 2025 guidance, now expecting 9-10% sales growth, 15-18% operating income growth, and improved free cash flow outlook. Despite a significant rally and fair 2026 valuation, CW offers 13% upside when considering 2027 earnings, supported by strong EBITDA and cash flow growth.

, /PRNewswire/ -- 

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of National Grid plc (NYSE: NGG) resulting from allegations that National Grid plc may have issued materially misleading business information to the investing public.

So What: If you purchased National Grid securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=41344 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

What is this about: On July 2, 2025, Reuters published an article entitled "'Preventable' National Grid failures led to Heathrow fire, findings say." The article stated that a "fire that shut London's Heathrow airport in March, stranding thousands of people, was caused by the UK power grid's failure to maintain an electricity substation, an official report said on Wednesday, prompting the energy watchdog to open a probe." Further, the article stated that the United Kingdom's Energy minister, Ed Miliband, had "called the report "deeply concerning", after it concluded that the issue which caused the fire was identified seven years ago but went unaddressed by power grid operator National Grid[.]"

On this news, National Grid American Depositary Shares' ("ADSs") fell 5%, on July 2, 2024.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions.  Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In PubMatic To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in PubMatic between February 27, 2025 and August 11, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Oct. 05, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against PubMatic, Inc. (“PubMatic” or the “Company”) (NASDAQ: PUBM) and reminds investors of the October 20, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) that a top DSP buyer was shifting a significant number of clients to a new platform which evaluated inventory differently; (2) that, as a result, PubMatic was seeing a reduction in ad spend and revenue from this top DSP buyer; and (3) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On August 11, 2025, after the market closed, PubMatic released its second quarter 2025 financial report. In its report, PubMatic’s Chief Financial Officer, Steven Pantelick, revealed that the Company’s outlook reflects “a reduction in ad spend from one of [its] top DSP partners.” The Company’s Chief Executive Officer, Rajeev Goel, further revealed that a “top DSP buyer” had “shifted a significant number of clients to a new platform that evaluates inventory differently” causing significant headwinds. Goel stated, in response to the inventory valuation change, the Company would “need to do a better job . . . to prioritize across all the hundreds of billions of daily ad impressions that we have, which subset of those impressions that we send to this DSP.”

On this news, PubMatic’s stock price fell $2.23, or 21.1%, to close at $8.34 per share on August 12, 2025, on unusually heavy trading volume.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding PubMatic’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the PubMatic class action, go to www.faruqilaw.com/PUBM or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5cffc24f-1f2f-4a65-9fc1-400954361ba2

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Quanex To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Quanex between December 12, 2024 and September 5, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Oct. 05, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Quanex Building Products Corporation (“Quanex” or the “Company”) (NYSE: NX) and reminds investors of the November 18, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the Company’s procedures and policies regarding tooling and equipment maintenance in its Tyman Mexico facility were significantly “underinvested”; (2) as a result, the Company’s tooling and equipment conditions had significantly degraded to near “catastrophic” levels; (3) that, as a result of the foregoing, the Company was likely to incur significant costs, “pushing out the timing” of expected benefits from the Tyman integration; (4) that Quanex had previously identified the foregoing issues; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On September 4, 2025, after the market closed, Quanex announced financial results for the third quarter of the 2025 fiscal year. Among other things, the Company disclosed “operational issues related to the legacy Tyman window and door hardware business in Mexico that are ongoing” which “impacted results more than expected during the third quarter of 2025.” Specifically, the Company reported a diluted EPS of ($6.04), compared to $0.77 in the prior year period and an adjusted EBIDTA of $70.30. The Company further disclosed that it was “adjusting for lower expected volumes and pushing out the timing of when [it] expect[s] to realize procurement savings” from the integration of the Tyman business.

Then, on September 5, 2025, the Company held an earnings call pursuant to the Company’s third quarter 2025 financial results. During the earnings call, Chief Executive Officer, George Wilson (“Wilson”) explained “operational challenges” in the Tyman facility in Mexico “negatively impacted EBITDA in the Hardware Solutions segment by almost $5 million in the third quarter alone.” Wilson further explained that the issue was previously “identified midyear” as it got “deeper into the integration” with Tyman, and described how the systems used to “anticipate and plan for tooling repairs” were significantly deficient, indicating it was near “nonexistent.” Wilson stated because Quanex was “underinvested” in “the tooling condition and the equipment condition” it “had to make some changes and fix some things before it was catastrophic.”

On this news, Quanex’s stock price fell $2.73, or 13.1%, to close at $18.18 per share on September 5, 2025, on unusually heavy trading volume. The stock price continued to decline on the subsequent trading day, falling $1.98 or 10.9%, to close at $16.20 per share on September 8, 2025, on unusually heavy trading volume.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding Quanex’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Quanex Building Products class action, go to www.faruqilaw.com/NX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5cffc24f-1f2f-4a65-9fc1-400954361ba2

EL SEGUNDO, Calif.--(BUSINESS WIRE)--Mattel, Inc. (NASDAQ: MAT) announced today that Barbie is celebrating International Day of the Girl by introducing Team Barbie – a coalition of four powerful role models and professional rugby players from across the globe to encourage girls to own their confidence proudly. The brand is honoring these incredible athletes who recognize and harness their own power with one-of-a-kind dolls made in their likeness because Barbie knows if you can see it, you can b.

SummaryI'm upgrading Marvell Technologies to a Strong Buy, as a key customer Microsoft ramps up custom AI chip (Maia) production, boosting MRVL's 2026 outlook.MRVL's revenue growth is set to accelerate, with potential FY26 revenues reaching $10.5B, per my estimates, driven by Maia and improving AI accelerator demand.Management signals confidence through $6B in buybacks, accelerated repurchases and increased insider buying, indicating a positive inflection for MRVL shares.Risks remain from competition and customer concentration, but MRVL's exclusive role in Microsoft's Maia program positions it for significant upside. wildpixel/iStock via Getty Images

Investment Thesis When the race for building out custom accelerator chips or AI ASICs (application-specific integrated circuits) started last year, the contest for ASIC supremacy quickly became a duopoly.

Broadcom (NASDAQ:AVGO) became the industry leader and still commands the

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in MRVL over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED BY, OR CONSTITUTE A VIOLATION OF, THE RELEVANT LAWS OF THAT JURISDICTION OR REQUIRE EURONEXT AND/OR ATHEX TO TAKE ANY FURTHER ACTION.

PLEASE SEE THE IMPORTANT DISCLAIMERS AT THE END OF THIS ANNOUNCEMENT.

EURONEXT N.V. HAS RECEIVED THE RELEVANT REGULATORY APPROVALS FOR THE
COMMENCEMENT OF THE ACCEPTANCE PERIOD OF THE VOLUNTARY SHARE EXCHANGE
OFFER FOR THE ORDINARY REGISTERED SHARES OF HELLENIC EXCHANGES-ATHENS STOCK
EXCHANGE S.A. IN CONSIDERATION FOR SHARES OF EURONEXT N.V.

THE ACCEPTANCE PERIOD WILL COMMENCE ON 6 OCTOBER 2025 AND WILL END ON 17
NOVEMBER 2025

6 October 2025

In accordance with Greek Law 3461/2006, as amended (the “Law”), on 30 July 2025 (the “Date of the Tender Offer”), Euronext N.V. (“Euronext” or the “Offeror”, and together with any and all of its directly, or indirectly, wholly, or partially, owned subsidiaries, the “Euronext Group”) announced the submission of a voluntary share exchange tender offer (the “Tender Offer”) to acquire all common registered shares, each having a nominal value of €0.42 (each, an “ATHEX Share”) of HELLENIC EXCHANGES-ATHENS STOCK EXCHANGE S.A. (“ATHEX” or the “Company” and together with its subsidiaries, the “ATHEX Group”), for newly issued ordinary shares in the capital of the Offeror, with a nominal value of €1.60 each (each, a “Consideration Share”) on a ratio of 0.050 Consideration Share for 1 ATHEX Share, in accordance with the Law.

Euronext announces that, following:

(a)      the issuance of a declaration of non-objection from the competent foreign authorities regarding the coordinated regulation and supervision of Euronext being the AMF, AFM, CBI, NFSA, FSMA, CMVM, and CONSOB on 2 October 2025, and

(b)      the approval by Hellenic Capital Market Commission (“HCMC”) of the information circular that Euronext has prepared in connection with the Tender Offer in accordance with the Law (the “Information Circular”) on 3 October 2025, and

Euronext has received all requisite regulatory approvals for the commencement of the Acceptance Period (as defined below).

Deutsche Bank AG is acting as advisor to Euronext in connection with the Tender Offer, in accordance with article 12 of the Law (the “Advisor”).

A summary of the expected timetable of principal events for the Tender Offer follows:

DateEvent3 October 2025Approval of the Information Circular by the HCMC6 October 2025Announcement of the Approval and Announcement of the Publication of the Information Circular6 October 2025Publication of Information Circular6 October 2025Publication of Euronext’s Exemption Document enabling the issuance of shares6 October 2025Commencement of the Acceptance Period17        November
2025End of the Acceptance Period19        November
2025Announcement of the results of the Tender Offer24        November
2025Registration of the transfer of the Transferred Shares to the securities account of the Offeror in the DSS.24        November
2025Delivery of the Consideration Shares to the Accepting Shareholders24        November
2025Commencement of listing and trading of the Consideration Shares on Euronext Amsterdam, Euronext Brussels, Euronext Lisbon and Euronext Paris. Note: The above date of 24 November presupposes that all approvals mentioned in section 7 below are met.

2.        Acceptance Period

2.1   The period of time during which the holders of ATHEX Shares (the “Shareholders”) may accept the Tender Offer by submitting a relevant written declaration of acceptance (the “Declaration of Acceptance”) to their intermediary (i.e. the bank, brokerage firm, investment services firm or other investment firm with which they cooperate) that is a certified member at the Greek Dematerialized Securities System (the “DSS Participant” and the “DSS”, respectively) through which their ATHEX Shares are registered, starts on 6 October 2025, at 08.00 am (Greek time) and ends on 17 November 2025, at 02:00 p.m. (Greek time) (the “Acceptance Period”).
2.2   Alternatively, for their own facilitation, Shareholders who wish to accept the Tender Offer may, at their own initiative, authorize their DSS Participant through which their ATHEX Shares are registered, to fill-in, sign, submit or dispatch the Declaration of Acceptance and in general to proceed with all necessary actions for the purpose of accepting the Tender Offer on their behalf. Declarations of Acceptance forms will be available through the DSS Participant throughout the Acceptance Period during business days and hours.

3.        The Tender Offer

3.1   As at the Date of the Tender Offer, no ATHEX Shares were held, directly or indirectly, by the Euronext Group.

3.2   The companies of the Euronext Group are acting in concert with the Offeror for the purposes of the Tender Offer, pursuant to article 2, case (e) of the Law. There are no other persons acting in concert with the Offeror for the purposes of the Tender Offer, pursuant to article 2, case (e) of the Law.

3.3   On 30 July 2025, the Offeror and ATHEX entered into a cooperation agreement which details the cooperation between the Offeror and ATHEX in relation to the Tender Offer (the “Cooperation Agreement”). The Cooperation Agreement provides, among others, that ATHEX will not tender the Treasury Shares in the Tender Offer.

3.4   The following members of the Board of Directors of ATHEX owning shares including CEO Ioannis Kontopoulos have provided irrevocable undertakings to tender their shares in the Tender Offer subject to the issuance of a reasoned opinion of ATHEX’s Board of Directors in favor of the Tender Offer:

NameNumber of shares heldGeorge Handjinicolaou15,000Ioannis Kontopoulos95,000 3.5   Other than the Cooperation Agreement and the aforementioned written statements received by the Offeror from the ATHEX directors, there are no special agreements relating to the Tender Offer or the exercise of rights arising from the ATHEX Shares to which the Offeror is a party.

4.        Consideration

4.1   In consideration for every ATHEX Share lawfully and validly tendered in the Tender Offer, and in accordance with the first clause of paragraph 1 of article 9 of the Law, Euronext offers 0.050 Consideration Share for 1 ATHEX Share (the “Offer Consideration”). The shares of the Offeror are held in book-entry form through the Central Securities Depository for the Offeror Shares (“Euronext Securities Milan”).

4.2   In the event that fractional balances of the Offeror's shares arise during the exchange, these will be paid by the Offeror based on the following formula:

the product of (x) the number of ATHEX Shares held by the investor, (y1) the volume-weighted average trading price (VWAP) of Euronext during the 1 week prior to the settlement date of the Public Offer and (y2) 0.050.

4.3   The Consideration Shares carry the right to dividends, capital returns, distributions from distributable reserves or other distributions that may be made by Euronext after the settlement date of the Tender Offer.

4.4   Euronext will assume payment of the duties levied in favor of the Hellenic Central Securities Depository S.A. (the “ATHEXCSD”) on the registration of the over-the-counter transfer of the Transferred Shares in accordance with the codified decision 18 (Meeting 311/22.02.2021) of the Board of Directors of ATHEXCSD, which would otherwise be payable by the accepting shareholders of ATHEX. Such duties amount to 0.08% and are calculated in accordance with the provisions of such decision with a minimum charge equal to the lower between €20 and 20% of the value of the transfer by any accepting shareholders per securities account.

4.5   To the contrary, it is clarified that shareholders who do not offer the ATHEX Shares they hold in the context of the Tender Offer, including those electing to receive the Cash Consideration in the context of the exercise of the Right of Squeeze-out or the Right to Sell-out, will also be responsible for all charges and taxes that are due in connection with the Tender Offer, including the duties above levied in favor of the Hellenic Central Securities Depository S.A and the Offeror assumes no responsibility nor liability in the payment of said charges and taxes. Notably, based on the letter of the circular issued by the Greek Independent Authority for Public Revenue with reference number Ε.2048/2024, the transfer of the Transferred Shares to the Offeror in consideration for Consideration Shares can be excluded from the tax provided for in article 9 paragraph 2 of Law 2579/1998 in favor of the Greek State provided all conditions mentioned therein are met, which amounts to 0.10%, and is imposed on sales of shares listed on the Athens Stock Exchange, since such transfer does not constitute a sale under the abovementioned provision. Shareholders are advised to consult their own tax advisors regarding the tax implications of the Tender Offer that may concern them in Greece or abroad.

4.6   It should be noted that an Accepting Shareholder who elects to receive Consideration Shares, or the financial intermediary (e.g. bank, brokerage firm, investment services firms, investment firm or other type of custodian) with whom such Accepting Shareholder cooperates, will have to inform, prior to the end of Acceptance Period, the Euronext Securities Milan participant with whom such shareholder has a direct or indirect relationship, of the receipt of the Consideration Shares through Euronext Securities Milan at the time settlement of the Tender Offer is completed. If it is not so informed, the said participant may reject the receipt of such shares, or the delivery thereof to such participant on behalf of the relevant Accepting Shareholder might not be possible.

5.        Information Circular

5.1   Beginning on 6 October 2025 and for the whole duration of the Acceptance Period, printed copies of the Information Circular will be available, free of charge, at any of the branches of Eurobank S.A. in Greece. In addition, the Information Circular will also be available through (i) the HCMC website

(www.hcmc.gr/el_GR/web/portal/deltia12minou),        (ii)        the        ATHEX        website
(https://www.athexgroup.gr/en/market-data/informative-material), (iii) the website of Eurobank (https://www.eurobank.gr/el/omilos/enimerosi-ependuton/enimerotika-deltia/diaxeiristis-trapezas- eurobank) and (iv) the website of the Offeror (www.euronext.com/en/athex-offer).

5.2   Further information about the acceptance of the Tender Offer can also be obtained through the dedicated helpline of the Offeror in Greece during Greek business days and hours by calling in Greece the following numbers:

If you are a retail investor:
Landline: + 30 21 1234 1979
Toll Free Number: + 30 800 8888001 (for landline callers in Greece)
DL: pto.athex@investor. sodali .com

If you are an institutional investor: +34 659 765 895

And through the DSS Participant whom such Accepting Shareholder cooperates during Greek business days and hours.
6.        Results of the Tender Offer

6.1   It is expected that the results of the Tender Offer will be announced on 19 November 2025 and the delivery of the Consideration Shares to the Accepting Shareholders will be completed on or about 24 November 2025, subject to the conditions mentioned in par. 7 below having been met.

7.        Prerequisite and Conditions

7.1   Completion of the Tender Offer is subject to the satisfaction of the following conditions and minimum number of shares:
(a)        the        approval        of the        HCMC in relation        to        the        direct change of control of ATHEX;
(b)        the        approval        of the        HCMC in relation        to        the        indirect change of control of ΑΤΗΕΧClear;
(c)        the        approval        of the        HCMC in relation        to        the        indirect change of control of ATHEXCSD;
(d)        the        approval        of RAEWW and the HCMC in        relation to the change of control of ATHEX due to its

participation in Hellenic Energy Exchange (“HenEx”) and EnEx Clearing House (“EnExClear”);
(e)   the approval of the HCMC in relation to the acquisition by the Euronext Reference ShareholdersI of an indirect qualifying holding between 20% and 50% of ATHEX, ATHEXCSD and ATHEXClear; (together with (a)-(e), the “Conditions”); and
(f)   no later than the end of the Acceptance Period, at least 38,759,500 ATHEX Shares, corresponding to at least 67% of ATHEX’s total voting rights whose exercise is not subject to suspension, shall have been lawfully and validly tendered to the Offeror (the “Minimum Number of Shares”). This condition may be amended in accordance with the provisions of the Law.

If (i) the Minimum Number of Shares is not fulfilled as at the end of the Acceptance Period and/or (ii) the Conditions are not satisfied, the Tender Offer will ipso jure lapse, and have no legal effect, and the ATHEX Shares which will have been tendered to the Offeror will be returned to their holders.

The Offeror may revoke the Tender Offer if (i) a competing offer, as provided by the Law, has been submitted, or (ii) subject to the HCMC’s approval, if an unforeseen change in circumstances beyond the control of the Offeror occurs that makes the Tender Offer particularly onerous.

The declarations of acceptance which are submitted cannot be revoked, unless a competing offer, as provided by the Law, has been submitted, in which case the accepting shareholder will be entitled to exercise a revocation right.

8.        Right of Squeeze-out - Right to Sell-out

8.1   If, at the end of the Acceptance Period, Euronext holds at least 52,065,000 ATHEX Shares representing at least 90% of ATHEX’s voting rights in accordance with the Law (the “Relevant Threshold”):

(a)   Euronext will initiate the squeeze-out procedure under the Law to cause any remaining holders of Company Shares to transfer those ATHEX Shares to Euronext, in accordance with the Law (the “Right of Squeeze-Out”); and

(b)   holders of ATHEX Shares who have not accepted the Tender Offer will be entitled, within a period of three (3) months from the publication of the results of the Tender Offer, to exercise the right to sell-out, in accordance with the Law (the “Right to Sell-Out”).

8.2   The consideration offered for each ATHEX Share regarding both the Right of Squeeze-Out and the Right to Sell-Out, is, at the election of the holder:

(a)        Consideration Shares held in book-entry form through Euronext Securities Milan; or

(b)        the cash consideration of €5.98 for each ATHEX Share (the “Cash Consideration”).

8.3   The Cash Consideration meets the criteria of the fair and reasonable consideration, according to article 9 of the Law, since:

(a)   it exceeds the VWAP during the six months preceding the Date of the Tender Offer, where in this case the VWAP of ATHEX Shares during the six months preceding 30 July 2025, is €5.9770

(b)   the Offeror or any persons acting on its behalf or in concert with the Offeror did not acquire ATHEX Shares during the twelve (12) months preceding the Date of the Tender Offer

(c)   a valuation is not required for ATHEX based on the provisions of par. 6 of article 9 of the Law, as none of the conditions referred to therein are met, namely:

- no sanctions have been imposed by the Board of Directors of the HCMC for manipulation that took place within the 18-month period preceding the Date of the Tender Offer,

during the six (6) months preceding the Date of the Tender Offer, (i) transactions in ATHEX Shares have been carried out on the Athens Stock Exchange on more than three-fifths (3/5) of the operating days of the relevant market, and specifically, they amounted to 100% of them and (ii) transactions that have been carried out on ATHEX Shares exceed ten percent (10%) of the total shares of ATHEX, and specifically, they amounted to 39% of them.The reasonable and fair consideration as determined by the criteria of paragraph 4 of Article 9 of the Law, exceeds eighty percent (80%) of the accounting value per share, based on the data of the average of the last two published financial statements of Law 3556/2007, on a consolidated basis. 8.4   If the Relevant Threshold is reached or exceeded at the end of the Acceptance Period, the Offeror expects that the Right of Squeeze-out process will be completed within four to eight weeks after Closing. The Offeror intends to apply for the commencement of unconditional listing and trading on Euronext Amsterdam, Euronext Brussels, Euronext Lisbon and Euronext Paris of any Offeror Shares which may be issued as consideration in connection with the Right of Squeeze-out as soon as practicable following completion of the Right of Squeeze-out process.
8.5   If the Relevant Threshold is reached or exceeded at the end of the Acceptance Period, the Right to Sellout will automatically expire upon completion of the Right of Squeeze-Out. As a result, the Offeror expects that completion of the Right to Squeeze-out process will precede the completion of the Right of Sell-out process.
9.        Delisting of the ATHEX Shares from the ATHEX

9.1   If, following completion of the Tender Offer or after the exercise of the Right of Squeeze-out or the Right to Sell-out, as the case may be, the Offeror holds at least 95% of ATHEX’s voting rights, the Offeror intends to request the convocation of a General Meeting of the Shareholders to resolve upon the submission of an application to the HCMC requesting the delisting of the ATHEX Shares from the Athens Stock Exchange, in accordance with article 17 paragraph 5 of Law 3371/2005, at which (General Meeting) the Offeror will exercise its voting rights in favor of such resolution.

9.2   If the percentage of the ATHEX Shares which will be eventually tendered ranges between 67% and below 90%, the ATHEX Shares will continue to trade on the ATHEX.

Important Notices

General

The Tender Offer described herein is addressed to holders of ATHEX Shares and only to persons to whom it may be lawfully addressed. The Tender Offer will be made in the territory of the Hellenic Republic. The making of the Tender Offer to specific persons who are residents in or nationals or citizens of jurisdictions outside the Hellenic Republic or to custodians, nominees or trustees of such persons (the “Excluded Shareholders”) may be made only in accordance with the laws of the relevant jurisdiction. It is the responsibility of the Excluded Shareholders and each person wishing to accept the Tender Offer to inform themselves of and ensure compliance with the laws of their respective jurisdictions in relation to the Tender Offer. If you have any doubts as to your status, you should consult with your professional advisor in the relevant jurisdiction.

The Tender Offer is not being made, directly or indirectly, by mail or by any means in or into any jurisdiction within which, under its laws, rules and regulations, the submission, the making or the presentation of the Tender Offer or the mailing or distribution of the Information Circular to be approved by the HCMC a declaration of acceptance and any other document or material relevant thereto (together, the “Relevant Documents”) is illegal or contravenes any applicable legislation, rule or regulation (together, the “Excluded Territories”). Accordingly, copies of any such Relevant Documents and materials will not be, and must not be, directly or indirectly, mailed, distributed or otherwise sent to anyone or from anyone in or into or from any Excluded Territory.

No Offeror Shares have been offered or will be offered pursuant to the Tender Offer to the public in the United Kingdom, except that the Offeror Shares may be offered to the public in the United Kingdom at any time: (a) to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation; (b) to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK Prospectus Regulation); or (c) in any other circumstances falling within Section 86 of the FSMA. Provided that no such offer of the Offeror Shares shall require Euronext or the Advisor to publish a prospectus pursuant to Section 85 of the FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. For the purposes of this provision, the expression an “offer to the public” in relation to the Offeror Shares in the United Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and any Offeror Shares to be offered so as to enable an investor to decide to purchase or subscribe for any Offeror Shares and the expression “UK Prospectus Regulation” means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.

The Consideration Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any state or other jurisdiction of the United States and may not be offered, sold or delivered, directly or indirectly, in or into the United States absent registration, or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state and other securities laws of the United States. This release does not constitute an offer to sell or solicitation of an offer to buy any of the Consideration Shares in the United States. Euronext has no intention to register any part of the Tender Offer in the United States or make a public offering of the Consideration Shares in the United States. Any Consideration Shares offered in the United States will be offered only to (i) holders of the Company Shares located outside of the United States and (ii) holders of Company Shares located within the United States that are “Qualified Institutional Buyers” (as defined in Rule 144A under the Securities Act). Such holders of Company Shares will be required to make such acknowledgements and representations to, and agreements with, Euronext as Euronext may require establishing that they are entitled to receive Consideration Shares pursuant to an exemption from or in a transaction not subject to the registration requirements of the Securities Act. Accordingly, any holder of Company Shares located within the United States who is not a Qualified Institutional Buyer or who does not make such acknowledgement and representation to establish their entitlement to receive the Consideration Shares is ineligible to participate in the Tender Offer, and any purported acceptance of the Tender Offer by such holder will be ineffective and disregarded.

The Tender Offer is being made in the U.S. in reliance on the expected availability of the Tier II exemption pursuant to Rule 14d-1(d) of, and otherwise in compliance with Section 14E of, and Regulation 14E promulgated under, the U.S. Securities and Exchange Act of 1934, as amended (the “Exchange Act”), and otherwise in accordance with the requirements of Greek law. The Tender Offer is not subject to Section 14(d)(1) of, or Regulation 14D promulgated under, the Exchange Act. The Company is not currently subject to the periodic reporting requirements under the Exchange Act and is not required to, and does not, file any reports with the SEC thereunder.

Pursuant to exemptive relief granted by the SEC from Rule 14e-5 under the Exchange Act, during the period of the Tender Offer, Euronext may purchase, or arrange to purchase, whether directly or through any of its affiliates, any broker or other financial institution acting as its agent or any affiliates of any broker or other financial institution acting as its agent, shares of the Company as permitted by applicable law. The Offeror Shares are issued to the Company's existing shareholders in Singapore without the intention of being on- sold there, and no documents issued by or on behalf of the Company may be used in any subsequent sale by these shareholders. The Information Circular has not been and will not be lodged with or registered as a prospectus under the Securities and Futures Act 2001 of Singapore with the Monetary Authority of Singapore. Therefore, the Information Circular does not constitute an offer or invitation for the sale or purchase of the Offeror Shares in Singapore, whether directly or indirectly, and shall not form the basis of any contract for the issue or sale of the Consideration Shares in Singapore.

The Offeror Shares may not be marketed, offered or sold directly or indirectly to the public in the People’s Republic of China (the “PRC”) and neither this announcement, which has not been submitted to the Chinese Securities and Regulatory Commission, nor any offering material or information contained herein relating to the issuance of the Offeror Shares, may be supplied to the public in the PRC or used in connection with any offer for the subscription or sale of shares to the public in the PRC. Offeror Shares may only be marketed, offered or sold to Chinese institution which are authorized to engage in foreign exchange, business and offshore investment from outside the PRC. Chinese investors may be subject to foreign exchange control approval and filing requirements under the relevant Chinese foreign exchange regulations, as well as offshore investment approval requirements.

This announcement is only made available to a limited number of "Professional Investors" within the meaning of the SCA’s Board of Directors Decision No. 13 of 2021 Concerning the Financial Activities Rule Book, as amended. By receiving this announcement, the entity to whom it has been issued understands, acknowledges and agrees that it has not been approved by or filed with the UAE Central Bank, the UAE Securities and Commodities Authority, the Dubai Financial Services Authority ("DFSA"), the Financial Services Regulatory Authority of Abu Dhabi ("FSRA") or any other relevant regulatory or licensing authorities in the UAE, nor has the originator, or any other related party received authorization or licensing from the UAE Central Bank, the UAE Securities and Commodities Authority, the DFSA, the FSRA, or any other authorities in the UAE. This announcement does not constitute a public offer of Offeror Shares in the UAE in accordance with the UAE SCA Chairman of the Board Resolution No. (11/R.M) of 2016 On the Regulations for Issuing and Offering Shares of Public Joint Stock Companies, Federal Decree-No. 32 of 2021 on Commercial Companies, or otherwise.

The announcement does not constitute a disclosure document for the purposes of the Australian Corporations Act 2001 (Corporations Act) and has not been submitted to the Australian Securities and Investments Commission. If you have received this announcement in Australia, you represent and warrant that you are an existing shareholder of ATHEX and that you are a sophisticated investor, professional investor, or another investor to whom disclosure is not required under Part 6D.2 of the Corporations Act.

The Offeror Shares may not be publicly offered, directly or indirectly, in Switzerland within the meaning of the Swiss Financial Services Act ("FinSA") and no application has or will be made to admit the Offeror Shares to trading on any trading venue (exchange or multilateral trading facility) in Switzerland. The Information Circular and any related offering or marketing materials regarding the Offeror Shares do not constitute a prospectus under the FinSA and must not be publicly distributed or made available in Switzerland.

The Offeror Shares have not been licensed for offering in Kuwait by the Kuwait Capital Markets Authority or any other relevant Kuwaiti government agency. The offering of the Offeror Shares in Kuwait on the basis a private placement or public offering is, therefore, restricted in accordance with Law No. 7 of 2010 and the bylaws thereto (as amended). No private or public offering of the Offeror Shares is being made in Kuwait, and no agreement relating to the sale of the Ordinary Shares will be concluded in Kuwait. No marketing or solicitation or inducement activities are being used to offer or market the Offeror Shares in Kuwait.

The Offeror Shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the Offeror Shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws.

The Offeror Shares have not been and will not be registered in Japan pursuant to Article 4, Paragraph 1 of the Financial Instruments and Exchange Act of Japan (Act No. 25 of 1948, as amended, the "FIEA") in reliance upon the exemption from the registration requirements since the offering constitutes the private placement to qualified institutional investors only as provided for in "i" of Article 2, Paragraph 3, Item 2 of the FIEA. A transferor of the Offeror Shares shall not transfer or resell them except where a transferee is a qualified institutional investor under Article 10 of the Cabinet Office Ordinance concerning Definitions provided in Article 2 of the Financial Instruments and Exchange Act of Japan (the Ministry of Finance Ordinance No. 14 of 1993, as amended).

This announcement does not constitute an invitation to the public in the Cayman Islands. Any invitation to participate in the Tender Offer is not being conducted in or from with the Cayman Islands or a place of business in the Cayman Islands.

No person receiving a copy of this announcement or of any Relevant Document in any jurisdiction outside the Hellenic Republic may treat any such document as if it constituted a solicitation or offer to such person and under no circumstances may such person use any Relevant Document if, in the relevant jurisdiction, such solicitation or offer may not be lawfully made to such person or if such Relevant Document may not be lawfully used without breaching any legal requirements. In those instances, any such Relevant Document is sent for information purposes only.

This regulatory announcement does not contain, constitute or form part of any offer or invitation to sell or subscribe or any solicitation of any offer to purchase or subscribe for any securities in any jurisdiction, and neither this regulatory announcement (nor any part of it) nor the fact of its distribution form the basis of, or may be relied upon in connection with, or act as any inducement to enter into, any contract or commitment whatsoever.

Cautionary Statement Regarding Forward-Looking Statements

The information contained in this announcement does not purport to be full or complete. The exact dates of the Tender Offer may change.

This announcement contains forward-looking statements which are subject to numerous assumptions, risks and uncertainties which change over time and relate to, amongst others, the business activities and certain plans and objectives that Euronext has in respect of the ATHEX Group and the Euronext Group. In some cases, the forward-looking statements may be identified by words such as “may”, “hope”, “might”, “can”, “could”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential” or “continue”, “intends” and the negative of these terms accordingly. There are many factors (for instance, without limitation, commercial, operational, economic, political and financial), as a consequence of which the actual results and the actual developments may potentially substantially differ from the plans and the objectives of Euronext and the ATHEX Group set out in this announcement. As such, Euronext and the ATHEX Group evolve in a highly competitive landscape and rapidly changing environment, where new risks and uncertainties not specifically described herein this announcement may emerge from time to time and it is not possible to predict all risks and uncertainties.

Although Euronext believes that, as of the date of this announcement, the expectations reflected in the forward-looking statements are reasonable, Euronext cannot assure you that future events will meet these expectations. Moreover, neither Euronext nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. After the date of this announcement, unless Euronext is required by applicable law to update these forward-looking statements, Euronext will not necessarily update any of these forward-looking statements to conform them either to actual results or to changes in expectations.

I As of 5 August 2025, the Euronext Reference Shareholders are the below:

ABN AMRO Bank N.V., through its subsidiary ABN AMRO Participaties Fund I B.V., holding 0.53% of capitalCaisse des Depots et Consignations, holding 8.25% of capitalCDP Equity, holding 8.25% of capitalSociete Federale de Participations et d’Investissement/ Federale Participatie - en Investeringsmaatschappij, holding 5.45% of capitalIntesa Sanpaolo, holding 1.58% of capital Hence, current Reference Shareholders' have an aggregated shareholding of 24.06%.

Legal announcement_Approval Prospectus and Acceptance period_ATHEX_6-10-2025

October 06, 2025 12:34 AM EDT | Source: LD Micro
Santa Monica, California and Addison, Texas--(Newsfile Corp. - October 6, 2025) - LD Micro, a premier resource for microcap investors and a wholly owned subsidiary of Freedom US Markets, and MDB Capital Holdings, LLC (NASDAQ: MDBH) ("MDB"), a public venture platform focused on launching category-leading "Big Idea" companies, today announced an important milestone nearly two decades in the making.

MDB has become LD Micro's 2,000th presenting company, marking a new chapter for a platform established in March 2006 by two visionaries seeking a better way to analyze the next generation of breakthrough companies.

"It has been a privilege to watch LD Micro evolve into a cornerstone of the microcap community over these many years," stated Chris Lahiji, Founder of LD Micro. "This platform was created out of a genuine passion for supporting innovative, high-potential businesses and connecting them with investors committed to the public microcap sector. Achieving the milestone of 2,000 presenters, particularly as the universe of U.S. public companies has decreased from 8,000 to approximately 4,000 over the past two decades, underscores our ongoing dedication. We are honored to have MDB Capital (MDBH) join us in celebrating this achievement, and we look forward to their participation at the Main Event at Hotel Del Coronado in less than two weeks."

"MDB Capital is honored to be the 2,000th company to present at LD Micro, a platform we have respected and worked alongside as part of our firm's journey," said Chris Marlett, CEO and Co-Founder of MDB. "For 28 years, MDB has been deeply committed to the microcap public markets, championing them as the preferred channel for game-changing companies to access growth capital. In a time when the number of public companies has declined sharply, we salute Chris Lahiji and the LD Micro team for their dedication in nurturing this ecosystem. We believe a major shift is underway: for today's most promising innovators, going public is once again emerging as a smarter, more impactful path than remaining private. That is precisely why, for the first time, MDB will be presenting at a microcap conference and we are thrilled to do so at LD Micro."

MDB will present at LD Micro on Tuesday, October 21, at 10:30 am.

About MDB Capital

Founded in 1997, MDB Capital focuses on launching "Big Ideas" through a unique approach to public venture capital. The firm emphasizes community-driven financings of early-stage leaders in significant business and technology categories via early public offerings, primarily on NASDAQ, as well as post-IPO offerings for qualifying companies. MDB Capital Holdings, LLC (NASDAQ: MDBH) and its subsidiaries-including MDB Capital, a venture-focused broker-dealer with the MDB Direct trading platform, and PatentVest, the first integrated IP strategy and law firm—operate under the MDB Capital brand. MDB Capital is a registered broker-dealer, Member FINRA/SIPC.

About LD Micro

LD Micro, a wholly owned subsidiary of Freedom US Markets, was founded in 2006 with the sole purpose of being an independent resource in the micro-cap space. Through the LD Micro Index and annual investor conferences, LD Micro has served as an invaluable asset to all those interested in discovering the next generation of great companies.

For more information on LD Micro, visit www.ldmicro.com.

LD Micro Company Contact:
Chris Lahiji, Co-founder LD Micro
[email protected]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/269121

SummaryWisdomTree U.S. MidCap Dividend Fund remains a buy, offering attractive valuation and higher yield versus the S&P 500 despite recent underperformance.DON's portfolio leans toward cyclical sectors like Financials, Industrials, and Consumer Discretionary, positioning it to benefit from strong GDP growth and potential Fed rate cuts.The ETF's technical picture is mixed, with key resistance at $53-$54 and a downward-trending 200-day moving average, but seasonal trends are favorable.Solid economic growth and declining Treasury yields support the investment thesis for DON as a value-oriented mid-cap dividend strategy into year-end. Getty Images

The bull market turns three years old next week. The SPDR S&P 500 ETF (SPY) has returned 96% from the closing low on October 12, 2022, to today. It has been a “Magnificent” rally, so to speak, as the Mag 7 have been the

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

TOKYO--(BUSINESS WIRE)--Mitsubishi Electric Corporation (TOKYO: 6503) announced today its development of the CielVision aerial display system. The system projects realistic images in mid-air with high brightness and high definition using new digital-optical technology that combines the company's proprietary aerial-projection optical technology with digital-image processing technology. By significantly improving the visibility of aerial images as well as downsizing the displays, Mitsubishi Elect.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Savara To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Savara between March 7, 2024 and May 23, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Oct. 05, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) and reminds investors of the November 7, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the MOLBREEVI BLA lacked sufficient information regarding MOLBREEVI’s chemistry, manufacturing, and/or controls; (2) accordingly, the FDA was unlikely to approve the MOLBREEVI BLA in its current form; (3) the foregoing made it unlikely that Savara would complete its submission of the MOLBREEVI BLA within the timeframe it had represented to investors; (iv) the delay in MOLBREEVI’s regulatory approval increased the likelihood that the Company would need to raise additional capital; and (v) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

On May 27, 2025, Savara issued a press release "announc[ing] that the Company received [a refusal to file] letter from the FDA for the [Biologics License Application] of MOLBREEVI as a therapy to treat patients with autoimmune PAP."

On this news, Savara's stock price fell $0.90 per share, or 31.69%, to close at $1.94 per share on May 27, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding Savara’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Savara class action, go to www.faruqilaw.com/SVRA or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5cffc24f-1f2f-4a65-9fc1-400954361ba2

The offering is being led by QCi's largest existing shareholders
Company's pro-forma cash position expected to be approximately $ 1.55 billion  following closing

, /PRNewswire/ -- Quantum Computing Inc. ("QCi" or the "Company") (Nasdaq: QUBT), an innovative, integrated photonics and quantum optics technology company, today announced that it has entered into securities purchase agreements with institutional investors for the purchase and sale of 37,183,937 shares of common stock in an oversubscribed private placement priced at the market under Nasdaq rules. The offering is expected to result in gross proceeds of $750 million, before deducting offering expenses. The closing of the offering is expected to occur on or about October 8, 2025, subject to the satisfaction of customary closing conditions.

The Company intends to use the net proceeds from the offering to fully fund commercialization, pursue strategic acquisitions, establish volume production capabilities, expand sales and engineering personnel, working capital, and general corporate purposes. 

Titan Partners Group, a division of American Capital Partners, is acting as the sole placement agent for the offering.

"Total capital raised since November 2024 is now $1.64 billion, positioning QCi with the strongest balance sheet among publicly traded quantum computing companies and providing what we believe is sufficient funding to execute our current business plan through 2028. The support from our existing investors through this recent raise is validation of our vision, technology, and roadmap. Our focus now shifts to expedite the transition from a quantum technology innovation company to a leading quantum hardware manufacturer, progressing our mission of putting quantum into the hands of people," said Dr. Yuping Huang, CEO and Chairman of the Board of QCi.

The securities issued in the private placement described above have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. The Company has agreed to file a resale registration statement with the SEC for purposes of registering the resale of the shares of common stock issued in connection with the private placement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Quantum Computing Inc.

Quantum Computing Inc. ("QCi" or the "Company") (Nasdaq: QUBT) is an innovative, integrated photonics and quantum optics technology company that provides accessible and affordable quantum machines and foundry services for the production of photonic chips based on thin-film lithium niobate (TFLN). QCi's products are designed to operate at room temperature and low power at an affordable cost. The Company's portfolio of core technologies and products offer unique capabilities in the areas of high-performance computing, artificial intelligence, and cybersecurity, as well as remote sensing applications.

About Titan Partners

Titan Partners Group, a division of American Capital Partners, is a boutique investment bank specializing in tailored solutions for publicly traded emerging growth companies. Titan Partners combines expertise, trust, dedication, and a forward-thinking approach to help clients achieve their strategic capital needs.

Forward-Looking Statements

This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements, generally identified by terms such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," "aim to," or variations of these or similar words, involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the expected closing of the offering, QCi's use of the net proceeds from the offering and the anticipated benefits that the Company may realize from the offering. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including having sufficient funding to execute our current business plan, the timing of orders and revenue, and the outcome of ongoing collaborations and demonstration projects with certain U.S. government agencies, academic institutions and commercial customers, and that actual results may differ materially from those contemplated by such forward-looking statements. Except as required by federal securities law, QCi undertakes no obligation to update or revise forward-looking statements to reflect changed conditions.

Company Contact:
Rosalyn Christian/John Nesbett
IMS Investor Relations
[email protected]

Titan Partners Contact:
[email protected]
4 World Trade Center, 29th Floor
New York, NY 10007
(929) 833-1246
www.titanpartnersgrp.com

SOURCE Quantum Computing Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Charter To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Charter between July 26, 2024 and July 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Oct. 05, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Charter Communications, Inc. (“Charter” or the “Company”) (NASDAQ: CHTR) and reminds investors of the October 13, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) the impact of the ACP end was a material event the Company was unable to manage or promptly move beyond; (ii) the ACP end was actually having a sustaining impact on Internet customer declines and revenue; (iii) neither was the Company executing broader operations in a way that would compensate for, or overcome the impact, of the ACP ending; (iv) the Internet customer declines and broader failure of Charter’s execution strategy created much greater risks on business plans and earnings growth than reported; (v) accordingly, the Company had no reasonable basis to state the Company was successfully executing operations, managing causes of Internet customer declines, or provide overly optimistic statements about the long term trajectory of the Company and EBITDA growth; and (iv) as a result of the foregoing, Defendants materially misled with, and/or lacked a reasonable basis for, their positive statements about the Company’s business, operations, outlook during the Class Period.

On July 25, 2025, Charter released its second quarter 2025 financial results, reporting that total internet customers had declined by 117,000, compared to about 100,000 in the second quarter of 2024, when adjusted to remove the prior year's impact of the end of the Affordable Connectivity Program. The Company's total video customers also decreased by 80,000.

On this news, Charter's stock price fell $70.25 per share, or 18.5%, to close at $309.75 per share on July 25, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding Charter’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Charter Communications class action, go to www.faruqilaw.com/CHTR or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5cffc24f-1f2f-4a65-9fc1-400954361ba2

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding In LifeMD To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in LifeMD between May 7, 2025 and August 5, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Oct. 05, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against LifeMD, Inc. (“LifeMD” or the “Company”) (NASDAQ: LFMD) and reminds investors of the October 27, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Defendants materially overstated LifeMD’s competitive position; (2) Defendants were reckless in raising LifeMD’s 2025 guidance, considering that they had not properly accounted for rising customer acquisition costs in LifeMD’s RexMD segment, as well as for customer acquisition costs related to the sale of drugs designed to treat obesity, including Wegovy and Zepbound; and (3) as a result, Defendants’ statements about LifeMD’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On August 5, 2025, after the market closed, LifeMD reported its financial results for the second quarter of 2025. In this announcement, LifeMD announced revised guidance. Among other metrics, LifeMD stated that it was expecting total revenue in the range of $250 to $255 million, compared with previous guidance of $268 to $275 million.

On this news, LifeMD's stock plummeted 44.8% on August 6, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding LifeMD’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the LifeMD class action, go to www.faruqilaw.com/LFMD or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5cffc24f-1f2f-4a65-9fc1-400954361ba2

Analyst’s Disclosure:I/we have a beneficial long position in the shares of IBIT, BTC-USD either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

NEW YORK, Oct. 05, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation (NYSE: EW).

SO WHAT: If you currently own shares of Edwards stock, please visit the firm’s website at https://rosenlegal.com/submit-form/?case_id=29704 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected].

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:        

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Oct. 05, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) and reminds investors of the November 17, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

According to the complaint, defendants made materially false and misleading statements regarding the timeline for the New Drug Application (“NDA”) submission and approval process for aficamten. Specifically, defendants represented that the Company expected approval from the U.S. Food and Drug Administration (“FDA”) for its NDA for aficamten in the second half of 2025, based on a September 26, 2025 PDUFA date, and failed to disclose material risks related to the Company’s failure to submit a Risk Evaluation and Mitigation Strategy (“REMS”) that could delay the regulatory process.

On May 6, 2025, during an earnings call, it was revealed that the Company had multiple pre-NDA meetings with the FDA discussing safety monitoring and risk mitigation but chose to submit the NDA without a REMS, relying on labeling and voluntary education materials. This confirmed defendants’ awareness of potential REMS requirements and their reckless decision to omit it from the initial submission, misleading investors about the regulatory timeline.

As a result of defendants’ false and misleading statements, class members purchased Cytokinetics’ common stock at artificially inflated prices and suffered significant losses when the truth was revealed.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding Cytokinetics’ conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Cytokinetics, Incorporated class action, go to www.faruqilaw.com/CYTK or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9e79d30e-c6e9-449b-91a9-563a45567b08

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In KBR To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in KBR between May 6, 2025 and June 19, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Oct. 05, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against KBR, Inc. (“KBR” or the “Company”) (NYSE: KBR) and reminds investors of the November 18, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Despite the knowledge that the U.S. Department of Defense’s Transportation Command (TRANSCOM) had, for months, had material concerns with HomeSafe’s ability to fulfill the Global Household Goods Contract, defendants claimed that the partnership was without issue, and would ramp up in future quarters; and (2) as a result, defendants statements about KBR’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

On June 19, 2025, after the market closed, HomeSafe issued a press release entitled “HomeSafe Alliance announces TRANSCOM’s Notice to Terminate Global Household Goods Contract.” The next day, before market hours, KBR issued a press release entitled “KBR Announcement on HomeSafe Alliance Global Household Goods Contract.”

On this news, the price of KBR stock fell $3.85 per share, or 7.29%, to close at $48.93 on June 20, 2025. On June 23, 2025, the next trading day, KBR stock fell a further $1.30, or 2.65%, to close at $47.63 on June 23, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding KBR’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the KBR class action, go to www.faruqilaw.com/KBR or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2835af11-efc3-4f40-a469-5790fc824fd8

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In MoonLake To Contact Him Directly To Discuss Their Options

If you suffered significant losses in MoonLake stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Oct. 05, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX).

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

Moonlake Immunotherapeutics saw its shares plummet over 80% on Monday after disappointing results from two late-stage trials of its experimental drug, sonelokimab, for hidradenitis suppurativa. While one study showed a statistically significant improvement over placebo, the margin of benefit fell short of investor expectations. The second trial failed to meet its primary endpoint entirely, with the company citing an unexpectedly high placebo response. The underwhelming data has cast doubt on the drug's regulatory path and commercial potential, prompting skepticism from analysts and a sharp market sell-off.

To learn more about the MoonLake investigation, go to www.faruqilaw.com/MLTX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5cffc24f-1f2f-4a65-9fc1-400954361ba2

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nutex To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Nutex between August 8, 2024 and August 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Oct. 05, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Nutex Health Inc. (“Nutex” or the “Company”) (NASDAQ: NUTX) and reminds investors of the October 21, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) HaloMD was achieving lucrative arbitration results for Nutex by engaging in a coordinated scheme to defraud insurance companies; (2) as a result, to the extent that they were the product of fraudulent conduct, revenues attributable to the Company's engagement with HaloMD in the IDR process were unsustainable; (3) in addition, the Company overstated the extent to which it had remediated, and/or its ability to remediate, the material weaknesses in its internal controls over financial reporting; (4) as a result, the Company was unable to effectively account for the treatment of certain of its stock based compensation obligations; (5) as a result, Nutex improperly calculated these stock based compensation obligations as equity rather than liabilities; (6) the foregoing increased the risk that the Company would be unable to timely file certain financial reports with the United States Securities and Exchange Commission ("SEC"); (7) accordingly, Nutex's business and/or financial prospects were overstated; and (8) as a result, Defendants' public statements were materially false and misleading at all relevant times.

On July 22, 2025, Blue Orca Capital ("Blue Orca") issued a short report on Nutex. The Blue Orca report alleges, among other things, that Nutex faces litigation risk due to its relationship with HaloMD, a third-party vendor that was recently sued for engaging in a "coordinated fraudulent scheme" to take millions from insurance companies on behalf of healthcare billing clients.

Following publication of the Blue Orca report, Nutex's stock price fell $11.18 per share, or 10.05%, to close at $100.01 per share on July 22, 2025.

On July 24, 2025, Nutex issued a press release responding to the Blue Orca Report, stating that it "strongly disagrees with the allegations in the report" and that it "expects to provide related updates in its upcoming earnings release and Form 10-Q for the second quarter of 2025 due on or before August 14, 2025."

However, after the market closed on August 14, 2025, Nutex announced that it would "delay filing its Form 10-Q for the period ending June 30, 2025", citing "non-cash accounting adjustments related to the treatment of stock-based compensation obligations for certain under-construction and ramping hospitals, as disclosed in previous filings."

When Nutex failed to rebut the allegations of the Blue Orca Report, the Company's stock price fell $18.22 per share, or 16.39%, to close at $92.91 per share on August 15, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding Nutex’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Nutex Health class action, go to www.faruqilaw.com/NUTX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5cffc24f-1f2f-4a65-9fc1-400954361ba2

The Oracle of Omaha probably won't ask for stock advice. But he'd probably like this stock.

Does Warren Buffett need help selecting stocks? Of course not. He's done a really good job of doing it all on his own for decades.

Sure, the legendary investor would likely insist that he's a "business picker" rather than a stock picker. Buffett would also probably point out that he has farmed out some of the decision-making to his two investment managers, Todd Combs and Ted Weschler, for quite a while.

But let's suppose that Buffett asked me to give him a hand choosing one stock to buy for Berkshire Hathaway's (NYSE: BRK.A) (NYSE: BRK.B) portfolio. If that wild scenario happened today, which stock would I recommend? I think I'd go with The Home Depot (HD -0.04%).

Image source: The Home Depot.

Why Home Depot would make a great Buffett stock
I view Home Depot as a great Buffett stock in part because it once was a Buffett stock. He initiated a position in the home improvement giant 20 years ago but eventually sold all of Berkshire's stake in the second quarter of 2009.

Buffett might wish he had held onto those shares in retrospect. Over the 14 years since he exited Berkshire's position in Home Depot, the stock has skyrocketed roughly 1,570%. That's more than double the gain delivered by Berkshire Hathaway itself. The Home Depot's total return, including reinvesting dividends, since Buffett bailed on the stock in 2009 is around 2,370%.

The Oracle of Omaha would probably like Home Depot's solid operating margin of 13.1%. I suspect that he would absolutely love the company's return on invested capital (ROIC) of around 31.2%.

We don't have to worry about Buffett not liking Home Depot's business. It's certainly one that he understands. Buffett has even recently bought stocks that benefit from some of the same trends as Home Depot -- homebuilders D.R. Horton (NYSE: DHI) and both share classes of Lennar (NYSE: LEN) (NYSE: LEN.B).

The median age of U.S. homes has increased quite a bit since Buffett last owned Home Depot. It stood at 41 years in 2023, according to the American Community Survey. Aging homes bode well for demand for home improvement products and supplies over the coming years.

The fly in the ointment
Is Home Depot the perfect Buffett stock? I wouldn't go that far. There is one fly in the ointment.

Like many stocks these days, Home Depot has a relatively high valuation. Its trailing 12-month price-to-earnings (P/E) ratio and its forward P/E are close to 26. Buffett learned from the father of value investing, Benjamin Graham. Would he balk at paying such a premium for Home Depot? Maybe, but maybe not.

Berkshire bought 12 stocks in Q2. Several of them were bargains that you'd expect Buffett to like. However, two had forward earnings multiples that have been consistently higher than Home Depot's all year: Heico (NYSE: HEI), which currently trades at a sky-high 66.8 times forward earnings estimates, and Pool Corp. (NASDAQ: POOL), which has a forward P/E of 28.7.

HD PE Ratio (Forward) data by YCharts

Perhaps Heico and Pool are part of the portfolio managed by Combs and Wexler. However, Buffett hasn't been afraid of paying more for quality in the past when he's been confident about a company's long-term earnings growth prospects.

Is Home Depot a good pick for every investor?
I selected Home Depot because it was a stock I thought would fit well with Buffett's investing style. Is this stock a good pick for every investor? Probably not.

I suspect that a purist value investor (which I don't think describes Buffett, by the way) would prefer to quickly move past Home Depot for the reasons already discussed. The home improvement retailer's dividend yield of 2.3% might not be juicy enough for some income investors. And growth-oriented investors can certainly find stocks that are more likely to deliver stronger earnings growth than Home Depot.

And even though Home Depot is the stock I'd pick for Buffett, I don't personally own it. I like the stock, but I like others more. And, unlike Buffett, I'm not sitting atop a cash stockpile of $344 billion.

Keith Speights has positions in Berkshire Hathaway. The Motley Fool has positions in and recommends Berkshire Hathaway, D.R. Horton, Home Depot, and Lennar. The Motley Fool recommends Heico. The Motley Fool has a disclosure policy.

LOS ANGELES, Oct. 05, 2025 (GLOBE NEWSWIRE) -- Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a California-based global shared intelligent electric mobility ecosystem company, today shared a weekly business update from YT Jia, Founder and Global Co-CEO of FF.

OSAKA, Japan--(BUSINESS WIRE)--Kyocera Document Solutions Inc. (President: Takashi Nagai) supported the production of dresses using artworks painted by artists contracted to HERALBONY for ANREALAGE's Collection at Paris Fashion Week SS 2026, held on September 30, 2025. The collection comprised 30 outfits, 26 of which used fabrics printed with our sustainable inkjet textile printer "FOREARTH". FOREARTH printing was used for bags and shoes, giving their designs an inner glow that attracted signif.